LLS Expands its Global Master Trial for Hard-To-Treat Leukemias in Children

The Leukemia & Lymphoma Society (LLS) announced today the first pediatric patient has received treatment in a new subtrial of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial (NCT04726241). PedAL is a first-of-its-kind integrated worldwide master trial that tests multiple targeted drugs simultaneously to accelerate treatments for leukemia, the most common childhood cancer.

Read more: https://www.prnewswire.com/news-releases/lls-expands-its-global-master-trial-for-hard-to-treat-leukemias-in-children-302433603.html